We are currently investigating BPL-003 (our novel intranasal formulation of 5-MeO-DMT) and ELE-101 (our novel intravenous formulation of psilocin) for Treatment Resistant Depression, Major Depressive Disorder and Alcohol Use Disorder.
Condition
Status
Product
Phase
Sex & age range
Location(s)
Link
Treatment Resistant Depression
Rec. Completed
BPL-003
IIb
M + F
18 – 75 years
Australia, Germany, Poland, Spain, UK, US
Phase IIa study of BPL-003 in patients with Treatment Resistant Depression
Recruiting
This open-label Phase IIa study is taking place at Hammersmith Medicines Research in London and MAC Clinical Research in Liverpool and will assess the safety, tolerability, efficacy and pharmacokinetics of a two-dose administration of BPL-003 in patients with Treatment Resistant Depression (TRD) who are not taking SSRIs. TRD is defined as a failure to respond to two or more pharmacological treatments within the current depressive episode.
Phase IIb study of BPL-003 in patients with Treatment Resistant Depression
Recruitment Completed
This randomised, dose-finding study will evaluate the effects of a single medium or high dose of BPL-003 against a sub-perceptual dose in patients with Treatment Resistant Depression (TRD). TRD is defined as a failure to respond to two or more pharmacological treatments within the current depressive episode. It is taking place at approximately 40 sites across Australia, Germany, Poland, Spain, the United Kingdom and the United States.
Links to other websites do not imply affiliation or endorsement. Beckley Psytech does not control and is not responsible for their content.
